What question did this study set out to answer?

To synthesize current clinical and translational knowledge on the pathophysiology, diagnostic tools, and therapeutic interventions for central disorders of hypersomnolence.

June 18, 2025Journal of Sleep ResearchOpen Access

Present and Future of Central Disorders of Hypersomnolence

View Full Paper

Ask AI

Bookmark

Authors

FBFrancesco BiscariniIstituto delle Scienze Neurologiche di Bologna LBLucie BarateauInserm FPFabio PizzaIstituto delle Scienze Neurologiche di Bologna

Discussion

Member takes

Implication

Review highlights evolving diagnostics and emerging orexin receptor agonists for central disorders of hypersomnolence, indicating shifts toward precision medicine.

Key Points

To synthesize current clinical and translational knowledge on the pathophysiology, diagnostic tools, and therapeutic interventions for central disorders of hypersomnolence.
Literature synthesis examining clinical criteria, neurophysiological markers, and natural histories of narcolepsy type 1, narcolepsy type 2, idiopathic hypersomnia, and Kleine-Levin syndrome.
Evaluation of established diagnostic techniques, including polysomnography and multiple sleep latency testing, alongside emerging wearables and quantitative neurophysiology.
Review of established symptomatic pharmacotherapies and pipeline disease-targeted compounds, notably orexin receptor agonists.
Hypocretin (orexin) deficiency secondary to hypothalamic neuronal loss is confirmed as a definitive biomarker for narcolepsy type 1, whereas the mechanisms for type 2 narcolepsy, idiopathic hypersomnia, and Kleine-Levin syndrome remain unresolved.
Standard testing relies heavily on sleep latency tests and polysomnography, though long-term recordings and digital wearable technologies present new avenues to improve diagnostic precision.
Therapeutic management is shifting from purely symptomatic wake-promoting agents and sodium oxybate toward targeted therapies that directly activate hypocretin/orexin signaling pathways.

Cite This Study

Biscarini et al. (2025) studied this question.

synapsesocial.com/papers/6a107dd78090e499da614239 https://doi.org/10.1111/jsr.70118

View Full Paper

Ask AI

Bookmark

Implication

Review highlights evolving diagnostics and emerging orexin receptor agonists for central disorders of hypersomnolence, indicating shifts toward precision medicine.

Present and Future of Central Disorders of Hypersomnolence

Discussion

Member takes

Implication

Key Points

Cite This Study

Present and Future of Central Disorders of Hypersomnolence

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider